



## **Aerie Pharmaceuticals to Participate in the H.C. Wainwright Ophthalmology Conference**

August 12, 2021

DURHAM, N.C.--(BUSINESS WIRE)--Aug. 12, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Casey C. Kocczynski, Ph.D., Chief Scientific Officer, will participate in a virtual panel discussion titled, "What are the Greatest Unmet Needs Facing Ophthalmology Today?", at the H.C. Wainwright Ophthalmology Conference. The panel will be held on Tuesday, August 17, 2021 at 9:00 a.m. Eastern Time.

The panel discussion will be webcast live and may be accessed by visiting Aerie's website at <http://investors.aeriepharma.com>. A replay of the panel discussion will be available for 10 business days.

### **About Aerie Pharmaceuticals, Inc.**

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa<sup>®</sup> (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa<sup>®</sup>, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa<sup>®</sup>, including the product label, is available at [www.rhopressa.com](http://www.rhopressa.com). Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan<sup>®</sup> (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa<sup>®</sup> and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan<sup>®</sup>, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan<sup>®</sup>, including the product label, is available at [www.rocklatan.com](http://www.rocklatan.com). Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. More information is available at [www.aeriepharma.com](http://www.aeriepharma.com).

View source version on [businesswire.com](https://www.businesswire.com): <https://www.businesswire.com/news/home/20210812005040/en/>

Ami Bavishi 908-947-3949; [abavishi@aeriepharma.com](mailto:abavishi@aeriepharma.com)

Source: Aerie Pharmaceuticals, Inc.